Capital Performance Advisors’s Pfizer PFE Stock Holding History

Capital Performance Advisors’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$381K	Sell	15,837 -4,351	-22%	-$114K	0.02%	199
2026 Q1	$567K	Sell	20,188 -3,317	-14%	-$88.3K	0.04%	206
2025 Q4	$585K	Buy	23,505 +6,408	+37%	+$162K	0.04%	193
2025 Q3	$436K	Buy	17,097 +6,040	+55%	+$149K	0.07%	149
2025 Q2	$268K	Sell	11,057 -2,082	-16%	-$48.6K	0.05%	177
2025 Q1	$333K	Sell	13,139 -7,368	-36%	-$193K	0.07%	148
2024 Q4	$544K	Buy	20,507 +12,333	+151%	+$335K	0.17%	55
2024 Q3	$237K	Buy	+8,174	New	+$238K	0.07%	101
2023 Q3	–	Sell	-5,568	Closed	-$204K	–	59
2023 Q2	$204K	Sell	5,568 -63	-1%	-$2.45K	0.1%	55
2023 Q1	$230K	Hold	5,631	–	–	0.12%	44
2022 Q4	$289K	Hold	5,631	–	–	0.17%	35
2022 Q3	$246K	Sell	5,631 -1,227	-18%	-$59.6K	0.16%	34
2022 Q2	$360K	Buy	6,858 +169	+3%	+$8.61K	0.22%	29
2022 Q1	$346K	Buy	6,689 +8	+0.1%	+$415	0.2%	28
2021 Q4	$357K	Buy	+6,681	New	+$331K	0.22%	26

Other funds holding PFE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Capital Performance Advisors's PFE Position: Q2 2026 in Review

Capital Performance Advisors reduced its Pfizer (PFE) stake by 22% in Q2 2026, selling an estimated $114K and leaving 15,837 shares worth $381K. The position accounts for 0.02% of the portfolio, ranked #199.

Capital Performance Advisors first reported a position in PFE in Q4 2021 and has held it in 15 quarters since. The position peaked at $585K in Q4 2025. 2,822 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

Capital Performance Advisors held 15,837 shares of Pfizer worth $381K as of Q2 2026.
Capital Performance Advisors sold 4,351 Pfizer shares in Q2 2026, an estimated $114K.
Pfizer made up 0.02% of Capital Performance Advisors's portfolio in Q2 2026, its #199 holding.
Capital Performance Advisors first reported a position in Pfizer in Q4 2021 and has held it in 15 quarters since.
Capital Performance Advisors's Pfizer position peaked at $585K in Q4 2025.
2,822 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Capital Performance Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.